bymuratdeniz ADMA Biologics, Inc. (NASDAQ:ADMA) specializes in developing and commercializing plasma-derived products for infectious diseases. However, ADMA’s market mostly focuses on immune-compromised patients. The company’s IP portfolio centers around three FDA-approved medications: Asceniv, Bivigam, and Nabi-HB. ADMA’s revenue streams primarily come from their FDA-approved products, with additional income from patented immunotechnology and contract development and manufacturing organization [CDMO] se ...

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s (ADMA) portfolio of marketed products and other pipeline updates when it reports second-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, namely – Bivigam (to ...

Adma Biologics (ADMA) closed the most recent trading day at $13.05, moving -1.81% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.78% for the day. On the other hand, the Dow registered a loss of 1.29%, and the technology-centric Nasdaq decreased by 0.7%.The infectious disease drug developer's shares have seen an increase of 25.14% over the last month, surpassing the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14%.Market participants will be ...

Finding millionaire-making stocks is not easy. While we can’t tell the future, we can do the next best thing: think forward, gauge a company’s room for growth, and determine how it intends to reach the next level. Here lies the beauty of mid-cap stocks, a market cap category sometimes overlooked in favor of large and mega caps. For the uninitiated, mid-cap stocks trade with a market cap between $2 billion and $10 billion. Some consider it the sweet spot between growth potential and stability because the bus ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adma Biologics (ADMA) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adma Biologics is one of 1026 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sect ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently ha ...

In the latest market close, Adma Biologics (ADMA) reached $10.84, with a -1.54% movement compared to the previous day. This change lagged the S&P 500's 0.16% gain on the day. Elsewhere, the Dow saw an upswing of 0.04%, while the tech-heavy Nasdaq appreciated by 0.49%.The the stock of infectious disease drug developer has risen by 15.77% in the past month, leading the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22%.The upcoming earnings release of Adma Biologics will be of great interest to in ...

Adma Biologics (ADMA) closed the latest trading day at $10.71, indicating a +0.85% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.25%. Elsewhere, the Dow saw an upswing of 0.77%, while the tech-heavy Nasdaq depreciated by 0.79%.Coming into today, shares of the infectious disease drug developer had gained 10.28% in the past month. In that same time, the Medical sector gained 0.03%, while the S&P 500 gained 3.59%.Analysts and investors alike will be ...

文章核心观点 - 华尔街分析师的推荐对投资者选择买入、卖出或持有股票有很大影响 [1] - 但分析师的推荐往往存在积极偏差,不能完全依赖 [5][10] - 使用Zacks Rank评级工具可以更好地预测股价走势 [7][11][12] 公司研究 - Adma Biologics目前的平均券商评级(ABR)为1.00,表示强烈买入 [2][3] - 但Zacks Rank评级为3(持有),表明公司未来业绩可能与大盘持平 [14][15][16] - 分析师对公司未来盈利预测保持稳定,这可能是公司短期内表现与大盘持平的合理原因 [15]

Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Titanium Metal Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global titanium metal market is expected to reach an estimated $2.4 billion by 2030 with a CAGR of 5.8% from 2024 to 2030.The major drivers for this market are rising use of titanium dioxide in the paints & coating industry, growing use of titanium metal in the aerospace & defense industry, as well as, increasing deman ...